BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells $15,803.20 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 581 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $27.20, for a total transaction of $15,803.20. Following the completion of the transaction, the chief financial officer now directly owns 122,766 shares in the company, valued at approximately $3,339,235.20. This represents a 0.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, November 12th, Troy Wichterman sold 147 shares of BioLife Solutions stock. The shares were sold at an average price of $26.19, for a total value of $3,849.93.
• On Wednesday, October 30th, Troy Wichterman sold 894 shares of BioLife Solutions stock. The stock was sold at an average price of $23.15, for a total value of $20,696.10.
• On Monday, September 16th, Troy Wichterman sold 611 shares of BioLife Solutions stock. The shares were sold at an average price of $25.12, for a total value of $15,348.32.

BioLife Solutions Price Performance

Shares of NASDAQ:BLFS opened at $27.47 on Friday. The firm has a 50 day moving average of $24.23 and a 200-day moving average of $23.24. The stock has a market capitalization of $1.27 billion, a PE ratio of -25.92 and a beta of 1.88. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 12 month low of $11.91 and a 12 month high of $28.88.

Analyst Upgrades and Downgrades

BLFS has been the subject of a number of recent research reports. HC Wainwright reduced their target price on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Craig Hallum boosted their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Northland Securities increased their target price on shares of BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Finally, TD Cowen lifted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat.com, BioLife Solutions presently has an average rating of “Moderate Buy” and a consensus target price of $27.50.

Institutional Investors Weigh In On BioLife Solutions

A number of large investors have recently modified their holdings of BLFS. Mark Sheptoff Financial Planning LLC acquired a new position in shares of BioLife Solutions during the 3rd quarter worth $28,000. 1620 Investment Advisors Inc. bought a new position in BioLife Solutions in the second quarter valued at about $35,000. Isthmus Partners LLC raised its stake in BioLife Solutions by 34.4% during the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 42,265 shares in the last quarter. Quest Partners LLC bought a new position in shares of BioLife Solutions in the third quarter worth about $57,000. Finally, GAMMA Investing LLC boosted its stake in shares of BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after purchasing an additional 748 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.